176 related articles for article (PubMed ID: 38594734)
21. Exploiting Gangliosides for the Therapy of Ewing's Sarcoma and H3K27M-Mutant Diffuse Midline Glioma.
Wingerter A; El Malki K; Sandhoff R; Seidmann L; Wagner DC; Lehmann N; Vewinger N; Frauenknecht KBM; Sommer CJ; Traub F; Kindler T; Russo A; Otto H; Lollert A; Staatz G; Roth L; Paret C; Faber J
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33572900
[TBL] [Abstract][Full Text] [Related]
22. Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.
Liu C; Kuang S; Huang T; Wu J; Zhang L; Gong X
CNS Neurosci Ther; 2024 Apr; 30(4):e14730. PubMed ID: 38644565
[TBL] [Abstract][Full Text] [Related]
23. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
Pachocki CJ; Hol EM
J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
[TBL] [Abstract][Full Text] [Related]
24. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
25. Pediatric midline H3K27M-mutant tumor with disseminated leptomeningeal disease and glioneuronal features: case report and literature review.
Navarro RE; Golub D; Hill T; McQuinn MW; William C; Zagzag D; Hidalgo ET
Childs Nerv Syst; 2021 Jul; 37(7):2347-2356. PubMed ID: 32989496
[TBL] [Abstract][Full Text] [Related]
26. Diffuse midline glioma H3K27M mutation in adult: A case report.
Bhattarai AM; Mainali G; Jha P; Karki P; Adhikari A; Pandit A; Bhattarai AM
Ann Med Surg (Lond); 2022 Apr; 76():103567. PubMed ID: 35495373
[TBL] [Abstract][Full Text] [Related]
27. Characterization of purine nucleotide metabolism in cultured fibroblasts with deficiency of hypoxanthine-guanine phosphoribosyltransferase and with superactivity of phosphoribosylpyrophosphate synthetase.
Zoref-Shani E; Sperling O
Enzyme; 1980; 25(6):413-8. PubMed ID: 6258915
[TBL] [Abstract][Full Text] [Related]
28. Amidophosphoribosyltransferase limits the rate of cell growth-linked de novo purine biosynthesis in the presence of constant capacity of salvage purine biosynthesis.
Yamaoka T; Kondo M; Honda S; Iwahana H; Moritani M; Ii S; Yoshimoto K; Itakura M
J Biol Chem; 1997 Jul; 272(28):17719-25. PubMed ID: 9211923
[TBL] [Abstract][Full Text] [Related]
29. Salvage capacity of hepatoma 3924A and action of dipyridamole.
Weber G; Lui MS; Natsumeda Y; Faderan MA
Adv Enzyme Regul; 1983; 21():53-69. PubMed ID: 6443595
[TBL] [Abstract][Full Text] [Related]
30. Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome.
Golbourn BJ; Halbert ME; Halligan K; Varadharajan S; Krug B; Mbah NE; Kabir N; Stanton AJ; Locke AL; Casillo SM; Zhao Y; Sanders LM; Cheney A; Mullett SJ; Chen A; Wassell M; Andren A; Perez J; Jane EP; Premkumar DRD; Koncar RF; Mirhadi S; McCarl LH; Chang YF; Wu YL; Gatesman TA; Cruz AF; Zapotocky M; Hu B; Kohanbash G; Wang X; Vartanian A; Moran MF; Lieberman F; Amankulor NM; Wendell SG; Vaske OM; Panigrahy A; Felker J; Bertrand KC; Kleinman CL; Rich JN; Friedlander RM; Broniscer A; Lyssiotis C; Jabado N; Pollack IF; Mack SC; Agnihotri S
Nat Cancer; 2022 May; 3(5):629-648. PubMed ID: 35422502
[TBL] [Abstract][Full Text] [Related]
31. The Korean Society for Neuro-Oncology (KSNO) Guideline for Adult Diffuse Midline Glioma: Version 2021.1.
Yoon HI; Wee CW; Kim YZ; Seo Y; Im JH; Dho YS; Kim KH; Hong JB; Park JS; Choi SH; Kim MS; Moon J; Hwang K; Park JE; Cho JM; Yoon WS; Kim SH; Kim YI; Kim HS; Sung KS; Song JH; Lee MH; Han MH; Lee SH; Chang JH; Lim DH; Park CK; Lee YS; Gwak HS;
Brain Tumor Res Treat; 2021 Apr; 9(1):1-8. PubMed ID: 33913265
[TBL] [Abstract][Full Text] [Related]
32. Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features.
Calmon R; Dangouloff-Ros V; Varlet P; Deroulers C; Philippe C; Debily MA; Castel D; Beccaria K; Blauwblomme T; Grevent D; Levy R; Roux CJ; Purcell Y; Saitovitch A; Zilbovicius M; Dufour C; Puget S; Grill J; Boddaert N
Eur Radiol; 2021 Dec; 31(12):8913-8924. PubMed ID: 34003354
[TBL] [Abstract][Full Text] [Related]
33. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
[TBL] [Abstract][Full Text] [Related]
34. Spinal Cord Diffuse Midline Glioma, H3K27M- mutant Effectively Treated with Bevacizumab: A Report of Two Cases.
Yabuno S; Kawauchi S; Umakoshi M; Uneda A; Fujii K; Ishida J; Otani Y; Hattori Y; Tsuboi N; Kohno S; Noujima M; Toji T; Yanai H; Yasuhara T; Date I
NMC Case Rep J; 2021; 8(1):505-511. PubMed ID: 35079510
[TBL] [Abstract][Full Text] [Related]
35. A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma.
Pal S; Kaplan JP; Nguyen H; Stopka SA; Savani MR; Regan MS; Nguyen QD; Jones KL; Moreau LA; Peng J; Dipiazza MG; Perciaccante AJ; Zhu X; Hunsel BR; Liu KX; Alexandrescu S; Drissi R; Filbin MG; McBrayer SK; Agar NYR; Chowdhury D; Haas-Kogan DA
Cancer Cell; 2022 Sep; 40(9):957-972.e10. PubMed ID: 35985342
[TBL] [Abstract][Full Text] [Related]
36. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
[TBL] [Abstract][Full Text] [Related]
37. An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect.
Rahal F; Capdevielle C; Rousseau B; Izotte J; Dupuy JW; Cappellen D; Chotard G; Ménard M; Charpentier J; Jecko V; Caumont C; Gimbert E; Grosset CF; Hagedorn M
Neurooncol Adv; 2022; 4(1):vdac018. PubMed ID: 35300150
[TBL] [Abstract][Full Text] [Related]
38. NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas.
Dahl NA; Donson AM; Sanford B; Wang D; Walker FM; Gilani A; Foreman NK; Tinkle CL; Baker SJ; Hoffman LM; Venkataraman S; Vibhakar R
J Neuropathol Exp Neurol; 2021 Mar; 80(4):345-353. PubMed ID: 33749791
[TBL] [Abstract][Full Text] [Related]
39. Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes.
Ajuyah P; Mayoh C; Lau LMS; Barahona P; Wong M; Chambers H; Valdes-Mora F; Senapati A; Gifford AJ; D'Arcy C; Hansford JR; Manoharan N; Nicholls W; Williams MM; Wood PJ; Cowley MJ; Tyrrell V; Haber M; Ekert PG; Ziegler DS; Khuong-Quang DA
Sci Rep; 2023 Mar; 13(1):3775. PubMed ID: 36882456
[TBL] [Abstract][Full Text] [Related]
40. Abnormal purine and pyrimidine nucleotide content in primary astroglia cultures from hypoxanthine-guanine phosphoribosyltransferase-deficient transgenic mice.
Pelled D; Sperling O; Zoref-Shani E
J Neurochem; 1999 Mar; 72(3):1139-45. PubMed ID: 10037486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
